Abstract
It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].
| Original language | English (US) |
|---|---|
| Title of host publication | Intraperitoneal Therapy for Ovarian Cancer |
| Publisher | Springer Berlin Heidelberg |
| Pages | 37-50 |
| Number of pages | 14 |
| ISBN (Print) | 9783642121296 |
| DOIs | |
| State | Published - 2010 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Intraperitoneal chemotherapy : Phase III trials. / Alberts, David S; Clouser, Mary C.
Intraperitoneal Therapy for Ovarian Cancer. Springer Berlin Heidelberg, 2010. p. 37-50.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Intraperitoneal chemotherapy
T2 - Phase III trials
AU - Alberts, David S
AU - Clouser, Mary C.
PY - 2010
Y1 - 2010
N2 - It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].
AB - It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].
UR - http://www.scopus.com/inward/record.url?scp=84895278070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895278070&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-12130-2_4
DO - 10.1007/978-3-642-12130-2_4
M3 - Chapter
AN - SCOPUS:84895278070
SN - 9783642121296
SP - 37
EP - 50
BT - Intraperitoneal Therapy for Ovarian Cancer
PB - Springer Berlin Heidelberg
ER -